Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
11.14
+0.48 (4.50%)
Dec 20, 2024, 4:00 PM EST - Market closed
Gyre Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Current | FY 2023 | FY 2022 |
Dec '24 Dec 20, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Market Capitalization | 956 | 1,967 | - |
Enterprise Value | 933 | 1,946 | - |
Last Close Price | 11.14 | 25.69 | - |
PS Ratio | 8.67 | 17.34 | - |
PB Ratio | 15.12 | 25.07 | - |
P/FCF Ratio | - | 113.23 | - |
P/OCF Ratio | 385.98 | 75.99 | - |
EV/Sales Ratio | 8.88 | 17.15 | - |
EV/EBITDA Ratio | 79.03 | 95.72 | - |
EV/EBIT Ratio | 89.89 | 101.27 | - |
EV/FCF Ratio | - | 111.99 | - |
Debt / Equity Ratio | 0.02 | 0.01 | 0.01 |
Debt / EBITDA Ratio | 0.14 | 0.02 | 0.06 |
Debt / FCF Ratio | - | 0.02 | 0.11 |
Asset Turnover | - | 1.13 | - |
Inventory Turnover | - | 0.89 | - |
Quick Ratio | 3.11 | 2.49 | 3.33 |
Current Ratio | 3.72 | 2.85 | 4.06 |
Return on Equity (ROE) | -85.32% | -113.45% | - |
Return on Assets (ROA) | - | 11.93% | - |
Return on Capital (ROIC) | 6.54% | 15.83% | - |
Earnings Yield | -9.29% | -4.72% | - |
FCF Yield | -0.23% | 0.88% | - |
Buyback Yield / Dilution | -28.56% | 13.02% | - |
Total Shareholder Return | -28.56% | 13.02% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.